BTIG Research downgraded the rating on Akebia Therapeutics to Neutral from Buy.
STA Research assigned a Speculative Buy rating on the company, with a 12 month target of $1.75 on the stock price.
Based on the Akebia Therapeutics Inc stock forecasts from 6 analysts, the average analyst target price for Akebia Therapeutics Inc is $4.67 over the next 12 months. Akebia Therapeutics Inc’s average analyst rating is Neutral. Stock Target Advisor’s own stock analysis of Akebia Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Akebia Therapeutics Inc’s stock price was USD 0.83. Akebia Therapeutics Inc’s stock price has changed by -1.64% over the past week, -1.62% over the past month and -75.51% over the last year.
What we like:
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What we don’t like:
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.